Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SIGA vs CRON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRON Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

CRON Overall Winner 6-Pillar Tally: SIGA 1 – 5 CRON Matrix Metrics: SIGA 1 – 9 CRON

As of Nov 20, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 46.2/100 (HOLD) at $2.40 (2.3x Forward P/E, -14.2% operating margin), whereas CRON carries 53.4/100 (HOLD) at $3.04 (12.0x Forward P/E, 6.1% operating margin).

  • Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.0); meanwhile CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 33.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SIGA vs CRON
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.40
-9.43% 1D
Market Cap $188.3M
TTM Revenue $52M
Forward P/E 2.3x
Beta / 30D Vol 0.90β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.2%), weak momentum, RSI 31
RSI-14: 31.0 · SMA20: $2.99 · SMA50: $3.13
CRON NASDAQ Head-to-Head Winner
Cronos Group Inc. Common Share
Medicinal Chemicals & Botanical Products
$3.04
-1.3% 1D
Market Cap $1.1B
TTM Revenue $206M
Forward P/E 12.0x
Beta / 30D Vol 0.36β · 38% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 27.0 Fund 47.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 33.9 · SMA20: $3.36 · SMA50: $3.32

6-Pillar Scorecard Institutional Category Breakdown (SIGA 1 – 5 CRON)

Columns: Metric · SIGA · CRON
1. Valuation Multiples SIGA
Forward P/E 2.3x 12.0x
Trailing P/E N/M 19.2x
PEG Ratio 3.37x N/M
EV / Revenue 1.4x 3.5x
2. Growth & Scale CRON
Revenue Growth (YoY) -49.7% +74.6%
Earnings Growth (YoY) -65.3% -44.7%
TTM Revenue (USD) $52M $206M
Market Cap $188.3M $1.1B
3. Profitability & Quality CRON
Gross Margin 23.4% 46.3%
Operating Margin -14.2% 6.1%
Net Profit Margin 1.3% 28.0%
Return on Equity (ROE) 0.4% 6.1%
4. Balance Sheet & Cash Flow CRON
Cash Generation (TTM) -$12M $65M
Cash Flow Margin -22.1% 31.6%
Net Cash / Leverage $116M Net Cash $410M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRON
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 94.8% (6th %ile) 45.3% (20th %ile)
Put/Call OI Skew 0.50x (Call-Skewed) 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat CRON
OpEx & R&D Intensity 37.6% of Rev ($20M) 40.2% of Rev ($83M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SIGA (1) vs CRON (9)
Institutional Metric SIGA CRON Criterion Row Edge
Market Capitalization
Scale
$188.3M $1.1B Larger Scale CRON
Trailing P/E Ratio
Valuation
N/M 19.2x Lower Multiple CRON
Forward P/E Ratio
Valuation
2.3x 12.0x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
-49.7% +74.6% Higher Growth CRON
Operating Margin (TTM)
Profitability
-14.2% 6.1% Higher Margin CRON
Net Profit Margin
Profitability
1.3% 28.0% Higher Margin CRON
Return on Equity (ROE)
Capital Efficiency
0.4% 6.1% Higher ROE CRON
52-Week Range Position
Momentum
2% ($2–$7) 47% ($2–$4) Stronger Trend CRON
Beta / 30D Volatility
Risk Regime
0.90β · 74% Vol 0.36β · 38% Vol Lower Realized Risk CRON
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 53.4 / 100 (HOLD) Higher Composite CRON
Trailing 12M Revenue (USD)
Operating Scale
$52M $206M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% 46.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.37x PEG · 1.4x EV/Rev N/M PEG · 3.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($116M Net Cash) $65M ($410M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRON +12.05 pp
SIGA: -23.81% · CRON: -11.76%
3M Horizon CRON +7.52 pp
SIGA: -18.37% · CRON: -10.85%
6M Horizon CRON +59.67 pp
SIGA: -48.72% · CRON: +10.95%
1Y Horizon CRON +88.2 pp
SIGA: -59.39% · CRON: +28.81%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SIGA Revenue CRON Revenue SIGA Op. Margin CRON Op. Margin Margin Leader
FY2018 $480M $10M 74.4% -168.7% SIGA
FY2019 $30M $20M -8.7% -645.5% SIGA
FY2020 $120M $50M 67.6% -469.6% SIGA
FY2021 $130M $60M 66.7% -452.2% SIGA
FY2022 $110M $90M 38.5% -128.4% SIGA
FY2023 $140M $90M 59.8% -97.2% SIGA
FY2024 $140M $120M 50.4% -65.1% SIGA
FY2025 $90M $150M 25.1% -11.9% SIGA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SIGA BREAKDOWN
34d in phase · OBV DISTRIBUTION
Current IV 94.8%
IV Percentile 6th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRON CONSOLIDATION
61d in phase · OBV DISTRIBUTION
Current IV 45.3%
IV Percentile 20th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $188.3M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published
CRON Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.1B market capitalization and 6.1% operating margin.
OpEx & R&D Reinvestment 40.2% of Rev ($83M)
90D Engineering Disclosures 0 Published

Investor FAQ SIGA vs CRON Key Questions & Quantitative Answers

As of Nov 20, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 46.2/100 (HOLD) at $2.40 (2.3x Forward P/E, -14.2% operating margin), whereas CRON carries 53.4/100 (HOLD) at $3.04 (12.0x Forward P/E, 6.1% operating margin). Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.0); meanwhile CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 33.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRON leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with CRON at +74.6% YoY revenue growth and -44.7% YoY earnings growth on $206M TTM revenue (46.3% gross margin, 6.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while CRON shifted +1400.0%. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus 40.2% of Rev ($83M) (0 disclosures) for CRON.

SIGA screens cheaper on headline valuation multiples. SIGA trades at 2.3x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas CRON trades at 12.0x Forward P/E, 19.2x Trailing P/E, N/M PEG, and 3.5x EV/Revenue (31.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus CRON (6.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SIGA carries 94.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.90β · 74% Vol realized risk). By comparison, CRON carries 45.3% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.36β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.